CoChat

Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment

Open access
Groop, P.‐H., Del Prato, S., Taskinen, M.‐R., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., Woerle, H.‐J. · 2014 · Diabetes, Obesity and Metabolism
Cited by 51

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose‐lowering drugs. The aim of this analysis was to evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)‐4 inhibitor linagliptin (5 mg/day) in mono, dual or triple oral glucose‐lowering regimens in subjects with T2DM and mild or moderate renal impairment (RI). Methods: In this pooled analysis of three 24‐week, placebo‐controlled, phase 3 trials, subjects with mild (estimated glomerular filtration rate (eGFR) 60–<90 ml/min/1.73 m 2, n = 838) or moderate RI (30–<60 ml/min/1.73 m 2, n = 93) were compared with subjects with normal renal function (≥90 ml/min/1.73 m 2, n = 1212). Results: Subjects with RI were older, had longer duration of diabetes, and increased prevalence of diabetes‐related comorbidities. After 24 weeks, linagliptin achieved consistent placebo‐corrected mean glycated haemoglobin (HbA1c) changes across the three renal function categories: normal (−0.63%; p < 0.0001), mild RI (−0.67%; p < 0.0001) and moderate RI (−0.53%; p < 0.01), with no inter‐group difference (p = 0.74). Renal function with linagliptin remained stable across all categories. In linagliptin‐treated subjects, overall adverse event (AE) rates and serious AE rates were similar to placebo. The incidence of hypoglycaemia with linagliptin and placebo was 11.1 versus 6.9%, 11.9 versus 9.0% and 15.9 versus 12.0% in the normal, mild RI and moderate RI categories, respectively. Conclusions: This pooled analysis provides evidence that linagliptin is an effective, well‐tolerated and convenient treatment in subjects with T2DM and mild or moderate RI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12281

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 51

Metadata

Authors
Groop, P. ‐., Del Prato, S., Taskinen, M. ‐., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., & Woerle, H. ‐.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-03-24
Volume
16
Issue
6
Pages
560-568
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2001209027
Cited by
51
References
10
FWCI
8.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment. https://app.cochat.ai/papers/10.1111/dom.12281
The paper
Groop, P. ‐., Del Prato, S., Taskinen, M. ‐., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., & Woerle, H. ‐. (2014). Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12281

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.